NCT03899155: Pan Tumor Rollover Study
- State
- Under way
- Phase
- Phase 2
- People
- 1,500 planned
- Started
- 9 Aug 2019
- Primary completion
- 25 Aug 2029
- Arms
- B1: Nivolumab + Ipilimumab, C5: Relatlimab + Nivolumab + Ipilimumab
- Results
- None posted
- 2 Apr 2019: Trial registered
- 9 Aug 2019: Trial started